Abstract
Juvenile-type diabetes is a contraindication to use of any oral hypoglycemic compound as the sole therapeutic agent. The best candidates for this therapy alone, without insulin, are diabetics whose disease appeared after the age of 40 years, is of less than 10 years' duration, and is stable, requiring small doses of insulin. Phenformin seems to enhance glucose utilization and to augment the action of endogenous or exogenous insulin; its use in obese diabetics has been recommended. In general, insulin-sulfonylurea combination therapy has not been effective. Phenformin-insulin therapy occasionally may be beneficial. A combination of sulfonylurea and phenformin also may be advantageous. Initial “loading doses” are no longer used.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
